Merus is a clinical-stage oncology company developing antibody therapeutics. Using its Biclonics® platform, Co. has produced and is developing the following candidates: MCLA-128 (zenocutuzumab) for the treatment of solid tumors that harbor Neuregulin 1 gene fusions; MCLA-117 for the treatment of acute myeloid leukemia; MCLA-158 for the treatment of solid tumors; and MCLA-145, developed in collaboration with Incyte Corporation, for the potential treatment of solid tumors and a hematological malignancy, B-cell lymphoma. Co. is also developing a late-stage pre-clinical candidate, MCLA-129 in collaboration with Betta Pharmaceuticals Co. Ltd., for the potential treatment of solid tumors. The MRUS stock yearly return is shown above.
The yearly return on the MRUS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MRUS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|